Application deadline: 13 January 2023
This position is part of the Discovery Medicine North Doctoral Training Partnership (DiMeN DTP), a diverse community of PhD students across the North of England researching the major health problems facing the world today.
About the Project
Cardiovascular disease is the leading cause of mortality and morbidity in developed countries. Often, the main pathological process responsible is the development of an arterial thrombus (or blood clot). The resultant blockage of arteries leads to drops in blood flow and eventual tissue death, such as in ischaemic stroke. There is a natural balance in the blood between agents that stimulate thrombus formation, and agents that break down clots (also known as thrombolysis). In disease, this balance can be disrupted leading to thrombus formation. As such, the usual treatment for such conditions is the use of anti-thrombotics to reduce the propensity for further thrombus formation. However, with an increasingly complex, multi-morbid and ageing population, balancing thrombotic and bleeding risks becomes more difficult. Therefore, being able to personalise risk and tailor treatment will aid clinicians in making right decisions and improving patient outcomes.
The Global Thrombosis Test (GTT) is a point-of-care test that measures a patient’s blood clotting capability and thrombolytic activity1,2. This project will use the GTT outputs of time-to-occlusion and time-to-lysis, along with patient data and mathematical models to predict patients at risk of arterial thrombotic events and their relative risk of anti-thrombotic use.
The objectives of the PhD will be split into 3 work packages:
WP1: Data collection - Sequential GTT in a post-stroke cohort
As part of an ongoing study at the University of Liverpool, the PhD candidate will analyse bloods taken from post-stroke patients using the GTT, obtaining personalised curves of time-to-occlusion and time-to-lysis for each patient. Patients will be followed up after 3 months for a second blood draw. Clinical outcomes assessing adverse cardiovascular events will be collected at 12 months.
WP2: Mathematical modelling - Personalised in silico model of thrombus formation and lysis
Using the data gathered, the candidate will build upon prior mathematical models of thrombus formation that are dependent on shear strain rate3. The parameters used to model thrombus formation and lysis will be fitted to patient data collected in WP1 – effectively developing personalised models of thrombus formation, lysis, and the impact of anti-thrombotics on an individual. These models will be used, in combination with blood flow models, to determine whether certain patients are at risk of heart attack and stroke in specific arterial regions (e.g. coronary arteries).
WP3: Machine learning - Clinical risk prediction
This WP will combine outcomes from WP1 and WP2 to predict clinical outcomes such as death and ischaemic events. The risk prediction model will be built using machine learning methods e.g. random forests and support vector machines. We will compare if the addition of GTT times and information from the personalised in silico models significantly improves risk prediction beyond that possible with standard clinical parameters4,5.
The work to be undertaken will be conducted at the Liverpool Centre for Cardiovascular Science as a collaboration between biomedical engineers (Dr El-Bouri, Dr Narracott) and clinical experts in cardiovascular disease and thrombosis (Prof Lip, Dr Gue, Prof Gorog). Training will be provided in using the GTT and in machine learning/mathematical modelling.
Interested to apply? Full information at this link
